CARBOPLATIN DOSING FOR ADULT JAPANESE PATIENTS

Article, Research English OPEN
ANDO, YUICHI ; SHIMOKATA, TOMOYA ; YASUDA, YOSHINARI ; HASEGAWA, YOSHINORI (2014)
  • Publisher: Nagoya University
  • Journal: Nagoya Journal of Medical Science, volume 76, issue 1-2, pages 1-9 (issn: 0027-7622, eissn: 2186-3326)
  • Related identifiers: pmc: PMC4345715
  • Subject: Invited Review Article | carboplatin | pharmacokinetics | creatinine clearance
    mesheuropmc: urologic and male genital diseases | female genital diseases and pregnancy complications

ABSTRACT Carboplatin is a platinum-based anticancer drug that has been long used to treat many types of solid cancer. Because the clearance of carboplatin strongly correlates with the glomerular filtration rate (GFR), its dosage is calculated with the Calvert formula on... View more
  • References (19)
    19 references, page 1 of 2

    1)Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res, 1984; 44: 1693–1697.

    2)Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E. Relationships between carboplatin exposure and tumor resp onse and toxicity in patients with ovarian cancer. J Clin Oncol, 1992; 10: 520–528.

    3)Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol, 1989; 7: 1748–1756.

    4)Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT, Mehta R, Mueller BA, Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int, 2011; 80: 1122–1137.

    5)Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron, 1976; 16: 31–41.

    6)Jelliffe RW. Estimation of creatinine clearance when urine cannot be collected. Lancet, 1971; 1: 975–976.

    7)Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis, 2009; 53: 982–992.

    8)Delanghe JR, Cobbaert C, Galteau MM, Harmoinen A, Jansen R, Kruse R, Laitinen P, Thienpont LM, Wuyts B, Weykamp C, Panteghini M. Trueness verification of actual creatinine assays in the European market demonstrates a disappointing variability that needs substantial improvement. An international study in the framework of the EC4 creatinine standardization working group. Clin Chem Lab Med, 2008; 46: 1319–1325.

    9)Ando Y, Minami H, Saka H, Ando M, Sugiura S, Sakai S, Shimokata K. Pharmacokinetic study of carboplatin given on a 5-day intravenous schedule. Jpn J Cancer Res, 1997; 88: 517–521.

    10)Ando Y, Minami H, Saka H, Ando M, Sakai S, Shimokata K. Adjustment of creatinine clearance improves accuracy of Calvert’s formula for carboplatin dosing. Br J Cancer, 1997; 76: 1067–1071.

  • Metrics
    No metrics available
Share - Bookmark